Celia Lin, MD

Title(s)Assistant Clinical Professor, Medicine
SchoolSchool of Medicine
Address4150 Clement Street, #101
San Francisco CA 94121
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of Rochester School of MedicineMD
    UCLABSGeneral Chemistry with Business and Administration Specialization
    UCLARheumatology Fellowship
    Boston Medical CenterInternal Medicine Residency
    Washington University in St. LouisRheumatology Fellowship and Post-doc

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024 Mar 27. Lafayette R, Barbour S, Israni R, Wei X, Eren N, Floege J, Jha V, Kim SG, Maes B, Phoon RK, Singh H, Tesar V, Lin CJ, Barratt J. PMID: 38552841.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    2. Prognostic and predictive markers of systemic sclerosis-associated interstitial lung disease in a clinical trial and long-term observational cohort. Rheumatology (Oxford). 2024 Feb 01; 63(2):472-481. Ghuman A, Khanna D, Lin CJF, Furst DE, Raghu G, Martinez FJ, Zucchetto M, Huang S, Jennings A, Nihtyanova SI, Denton CP. PMID: 37228011; PMCID: PMC10836965.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    3. Biomarkers of fibrosis, inflammation, and extracellular matrix in the phase 3 trial of tocilizumab in systemic sclerosis. Clin Immunol. 2023 09; 254:109695. Sheng XR, Gao X, Schiffman C, Jiang J, Ramalingam TR, Lin CJF, Khanna D, Neighbors M. PMID: 37479123.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCellsCTClinical Trials
    4. Atacicept-it's not over until the wolf-lady sings (or maybe howls). Rheumatology (Oxford). 2023 04 03; 62(4):1359-1361. Isenberg DA, Lin CJF. PMID: 36087007.
      View in: PubMed   Mentions: 1     Fields:    
    5. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial. Am J Respir Crit Care Med. 2022 03 15; 205(6):674-684. Khanna D, Lin CJF, Furst DE, Wagner B, Zucchetto M, Raghu G, Martinez FJ, Goldin J, Siegel J, Denton CP. PMID: 34851799.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    6. Prognostic and Predictive Biomarkers in Patients With Coronavirus Disease 2019 Treated With Tocilizumab in a Randomized Controlled Trial. Crit Care Med. 2022 03 01; 50(3):398-409. Tom J, Bao M, Tsai L, Qamra A, Summers D, Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings W, Blyth KG, Carratalà J, François B, Benfield T, Haslem D, Bonfanti P, van der Leest CH, Rohatgi N, Wiese L, Luyt CE, Kheradmand F, Rosas IO, Cai F. PMID: 34612846; PMCID: PMC8855771.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCellsCTClinical Trials
    7. Safety and Efficacy of Tocilizumab 4 or 8 mg/kg in Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019 Pneumonia: A Randomized Clinical Trial. Open Forum Infect Dis. 2022 Jan; 9(1):ofab608. Kumar PN, Hernández-Sánchez J, Nagel S, Feng Y, Cai F, Rabin J, Morse CG, Nadig NR, Ashraf O, Gotur DB, McComsey GA, Gafoor K, Perin P, Thornton SC, Stubbings W, Lin CJF, Tsai L. PMID: 35024375; PMCID: PMC8690270.
      View in: PubMed   Mentions: 9  
    8. Tocilizumab Prevents Progression of Early Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheumatol. 2021 07; 73(7):1301-1310. Roofeh D, Lin CJF, Goldin J, Kim GH, Furst DE, Denton CP, Huang S, Khanna D, focuSSced Investigators. PMID: 33538094; PMCID: PMC8238790.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansCTClinical Trials
    9. New composite endpoint in early diffuse cutaneous systemic sclerosis: revisiting the provisional American College of Rheumatology Composite Response Index in Systemic Sclerosis. Ann Rheum Dis. 2021 05; 80(5):641-650. Khanna D, Huang S, Lin CJF, Spino C. PMID: 33257497; PMCID: PMC10750249.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    10. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2020 10; 8(10):963-974. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, Allanore Y, Matucci-Cerinic M, Distler O, Shima Y, van Laar JM, Spotswood H, Wagner B, Siegel J, Jahreis A, Denton CP, focuSSced investigators. PMID: 32866440.
      View in: PubMed   Mentions: 172     Fields:    Translation:HumansCTClinical Trials
    11. Characterizing Disease Manifestations and Treatment Patterns Among Adults with Systemic Sclerosis: A Retrospective Analysis of a US Healthcare Claims Population. Rheumatol Ther. 2020 Mar; 7(1):89-99. Gale SL, Trinh H, Mathew N, Jahreis A, Lin CJF, Sarsour K. PMID: 31734871; PMCID: PMC7021840.
      View in: PubMed   Mentions: 4  
    12. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group. Osteoporos Int. 2019 Sep; 30(9):1855-1864. Bilezikian JP, Lin CJF, Brown JP, Wang AT, Yin X, Ebeling PR, Fahrleitner-Pammer A, Franek E, Gilchrist N, Miller PD, Simon JA, Valter I, Zerbini CAF, Libanati C, Chines A. PMID: 31201481; PMCID: PMC6719332.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    13. Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment. J Bone Miner Res. 2019 06; 34(6):1033-1040. Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, de Greg?rio LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM. PMID: 30919997; PMCID: PMC6852155.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    14. Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez. Ann Rheum Dis. 2019 11; 78(11):e124. Khanna D, Jahreis A, Lin CJF. PMID: 30352886.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    15. Occurrence of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologics and Denosumab Observed in a Clinical Setting. J Rheumatol. 2018 Feb; 45(2):170-176. Lau AN, Wong-Pack M, Rodjanapiches R, Ioannidis G, Wade S, Spangler L, Balasubramanian A, Pannacciulli N, Lin CJF, Roy-Gayos P, Bensen WG, Bensen R, Adachi JD. PMID: 29142041.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    16. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann Rheum Dis. 2018 02; 77(2):212-220. Khanna D, Denton CP, Lin CJF, van Laar JM, Frech TM, Anderson ME, Baron M, Chung L, Fierlbeck G, Lakshminarayanan S, Allanore Y, Pope JE, Riemekasten G, Steen V, Müller-Ladner U, Spotswood H, Burke L, Siegel J, Jahreis A, Furst DE. PMID: 29066464; PMCID: PMC5867414.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    17. Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study. BMC Musculoskelet Disord. 2017 04 27; 18(1):174. Adachi JD, Bone HG, Daizadeh NS, Dakin P, Papapoulos S, Hadji P, Recknor C, Bolognese MA, Wang A, Lin CJF, Wagman RB, Ferrari S. PMID: 28449657; PMCID: PMC5408481.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    18. Glucocorticoid exposure and fracture risk in patients with new-onset rheumatoid arthritis. Osteoporos Int. 2016 11; 27(11):3239-3249. Balasubramanian A, Wade SW, Adler RA, Lin CJF, Maricic M, O'Malley CD, Saag K, Curtis JR. PMID: 27273113.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    19. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015 Dec; 26(12):2773-83. Papapoulos S, Lippuner K, Roux C, Lin CJ, Kendler DL, Lewiecki EM, Brandi ML, Czerwinski E, Franek E, Lakatos P, Mautalen C, Minisola S, Reginster JY, Jensen S, Daizadeh NS, Wang A, Gavin M, Libanati C, Wagman RB, Bone HG. PMID: 26202488; PMCID: PMC4656716.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    20. Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. Nat Immunol. 2011 Oct 23; 12(12):1184-93. Hammer GE, Turer EE, Taylor KE, Fang CJ, Advincula R, Oshima S, Barrera J, Huang EJ, Hou B, Malynn BA, Reizis B, DeFranco A, Criswell LA, Nakamura MC, Ma A. PMID: 22019834; PMCID: PMC3419270.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansAnimalsCells
    21. Binding and uptake of H-ferritin are mediated by human transferrin receptor-1. Proc Natl Acad Sci U S A. 2010 Feb 23; 107(8):3505-10. Li L, Fang CJ, Ryan JC, Niemi EC, Lebrón JA, Björkman PJ, Arase H, Torti FM, Torti SV, Nakamura MC, Seaman WE. PMID: 20133674; PMCID: PMC2840523.
      View in: PubMed   Mentions: 176     Fields:    Translation:HumansCells
    22. Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity. J Immunol. 2009 Sep 01; 183(5):3150-9. Liszewski MK, Leung MK, Hauhart R, Fang CJ, Bertram P, Atkinson JP. PMID: 19667083; PMCID: PMC2899487.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    23. Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine. 2008 Dec 30; 26 Suppl 8:I22-7. Liszewski MK, Fang CJ, Atkinson JP. PMID: 19388160; PMCID: PMC2768381.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    24. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol. 2008 Nov; 143(3):336-48. Fang CJ, Richards A, Liszewski MK, Kavanagh D, Atkinson JP. PMID: 18691170.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    25. Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndrome. Blood. 2008 Jan 15; 111(2):624-32. Fang CJ, Fremeaux-Bacchi V, Liszewski MK, Pianetti G, Noris M, Goodship TH, Atkinson JP. PMID: 17914026; PMCID: PMC2200836.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansCells
    26. Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Mol Immunol. 2007 Jan; 44(1-3):111-22. Richards A, Kathryn Liszewski M, Kavanagh D, Fang CJ, Moulton E, Fremeaux-Bacchi V, Remuzzi G, Noris M, Goodship TH, Atkinson JP. PMID: 16882452.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    27. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006 Aug 15; 108(4):1267-79. Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, Mele C, Bresin E, Cassis L, Gamba S, Porrati F, Bucchioni S, Monteferrante G, Fang CJ, Liszewski MK, Kavanagh D, Atkinson JP, Remuzzi G, International Registry of Recurrent and Familial HUS/TTP. PMID: 16621965; PMCID: PMC1895874.
      View in: PubMed   Mentions: 261     Fields:    Translation:HumansCellsCTClinical Trials
    28. Manipulation of immune regulation in systemic lupus erythematosus. Autoimmun Rev. 2005 Nov; 4(8):515-9. La Cava A, Fang CJ, Singh RP, Ebling F, Hahn BH. PMID: 16214088.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansAnimalsCells
    29. The rationale for renewed interest by physicians in nutrition. Curr Atheroscler Rep. 1999 Nov; 1(3):173-5. Pearson TA, Bloch R, Dorantes J, Gordian A, Fang C, Swanson J, Brown K. PMID: 11122707.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    30. The effects of graded hypoxia on intraparenchymal arterioles in rat brain slices. Neuroreport. 1998 May 11; 9(7):1419-23. Staunton M, Dulitz MG, Fang C, Schmeling WT, Kampine JP, Farber NE. PMID: 9631440.
      View in: PubMed   Mentions: 2     Fields:    Translation:Animals
    31. Conformation of T4 lysozyme in solution. Hinge-bending motion and the substrate-induced conformational transition studied by site-directed spin labeling. Biochemistry. 1997 Jan 14; 36(2):307-16. Mchaourab HS, Oh KJ, Fang CJ, Hubbell WL. PMID: 9003182.
      View in: PubMed   Mentions: 68     Fields:    Translation:Cells
    Celia's Networks
    Concepts (190)
    Derived automatically from this person's publications.
    _
    Co-Authors (10)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _